ABBOTT LABORATORIES ABT
Pharmaceutical Preparations · NYSE
Revenue
$40.11B
-8.1% YoY
Net income
$5.72B
-17.5% YoY
Total assets
$81.41B
+11.2% YoY
EPS
3.26
-16.6% YoY
Advertisement
Income Statement
| Period | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 | 2024 Q2 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $10.36B | $40.11B | $30.98B | $20.34B | $9.96B | $43.65B | $29.87B | $19.73B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| R&D Expense | $716.00M | $2.74B | $2.10B | $1.38B | $684.00M | $2.89B | $2.04B | $1.37B |
| SG&A Expense | $3.06B | $10.95B | $8.79B | $5.89B | $2.96B | $11.25B | $8.22B | $5.50B |
| Operating Income (Loss) | $1.69B | $6.48B | $4.91B | $3.06B | $1.39B | $8.36B | $4.70B | $3.05B |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $1.32B | $5.72B | $4.17B | $2.53B | $1.23B | $6.93B | $4.13B | $2.69B |
| EPS (Diluted) | 0.76 | 3.26 | 2.38 | 1.44 | 0.70 | 3.91 | 2.35 | 1.53 |
Balance Sheet
| Period | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 | 2024 Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $86.71B | $81.41B | $81.41B | $81.41B | $81.41B | $73.21B | $73.21B | $73.21B |
| Current Assets | $26.00B | $23.66B | $23.66B | $23.66B | $23.66B | $22.67B | $22.67B | $22.67B |
| Cash & Equivalents | $8.52B | $7.62B | $7.62B | $7.62B | $7.62B | $6.90B | $6.90B | $6.90B |
| Accounts Receivable | $7.93B | $6.92B | $6.92B | $6.92B | $6.92B | $6.57B | $6.57B | $6.57B |
| Inventory | $6.49B | $6.19B | $6.19B | $6.19B | $6.19B | $6.57B | $6.57B | $6.57B |
| PP&E (Net) | $11.82B | $10.66B | $10.66B | $10.66B | $10.66B | $10.15B | $10.15B | $10.15B |
| Goodwill | $24.04B | $23.11B | $23.11B | $23.11B | $23.11B | $23.68B | $23.68B | $23.68B |
| Current Liabilities | $16.50B | $14.16B | $14.16B | $14.16B | $14.16B | $13.84B | $13.84B | $13.84B |
| Long-Term Debt | — | $14.12B | — | — | — | $14.68B | — | — |
| Stockholders Equity | $52.13B | $47.66B | $47.66B | $47.66B | $47.66B | $38.60B | $38.60B | $38.60B |
Cash Flow Statement
| Period | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 | 2024 Q2 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.42B | $7.26B | $5.69B | $2.98B | $1.02B | $9.58B | $4.22B | $2.35B |
| Investing Cash Flow | $-470.00M | $-3.13B | $-1.47B | $-878.00M | $-425.00M | $-1.74B | $-2.31B | $-1.68B |
| Financing Cash Flow | $-2.06B | $-7.09B | $-3.54B | $-1.97B | $-1.18B | $-7.64B | $-5.04B | $-2.70B |
| Stock Repurchases | $280.00M | $1.23B | $980.00M | $229.00M | $226.00M | $3.79B | $968.00M | $966.00M |
Similar companies
AbbVie Inc.
ABBV
BRISTOL MYERS SQUIBB CO
BMY
JOHNSON & JOHNSON
JNJ
ELI LILLY & Co
LLY
Merck & Co., Inc.
MRK
PFIZER INC
PFE
REGENERON PHARMACEUTICALS, INC.
REGN
VERTEX PHARMACEUTICALS INC / MA
VRTX
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.